{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T14:59:46Z","timestamp":1787497186761,"version":"build-2736575974"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","license":[{"start":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T00:00:00Z","timestamp":1753056000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Kidney360"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:p>In Canada, tolvaptan (JINARC) is approved for the treatment of adults with autosomal dominant polycystic kidney disease to slow the progression of kidney enlargement and kidney function decline. Safety data from the pivotal Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and Its Outcomes (TEMPO 3:4) study suggested the potential for increased risk of liver injury with tolvaptan, which led to the establishment of the Canadian Hepatic Safety Monitoring and Distribution Programme in 2015. This review summarizes data regarding hepatic safety from clinical trials and presents data from established risk mitigation programs and real-world evidence. Data show that frequent liver function monitoring allows timely detection of drug-induced liver injury and prompt treatment interruption. To date, this approach has led to the absence of serious liver injury or liver failure in more than 2800 patients treated with tolvaptan in Canada over the past 10 years.<\/jats:p>","DOI":"10.34067\/kid.0000000934","type":"journal-article","created":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T16:00:42Z","timestamp":1753113642000},"page":"2263-2273","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Long-Term Experience of Tolvaptan"],"prefix":"10.34067","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0283-4530","authenticated-orcid":false,"given":"Pierre Antoine","family":"Brown","sequence":"first","affiliation":[{"name":"Division of Nephrology, Department of Medicine, Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5692-3416","authenticated-orcid":false,"given":"Suzy","family":"Bubolic","sequence":"additional","affiliation":[{"name":"Otsuka Canada Pharmaceutical Inc., Saint-Laurent, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-7987-2404","authenticated-orcid":false,"given":"Annick","family":"Laplante","sequence":"additional","affiliation":[{"name":"Otsuka Canada Pharmaceutical Inc., Saint-Laurent, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6181-4859","authenticated-orcid":false,"given":"Thomas","family":"Jaeger","sequence":"additional","affiliation":[{"name":"Otsuka Pharma GmbH, Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1075-6963","authenticated-orcid":false,"given":"Ahsan","family":"Alam","sequence":"additional","affiliation":[{"name":"Division of Nephrology, McGill University Health Centre, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,7,21]]},"reference":[{"issue":"3","key":"B1-20260109","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1124\/jpet.109.162651","article-title":"Intrinsic versus idiosyncratic drug-induced hepatotoxicity--two villains or one?","volume":"332","author":"Roth","year":"2010","journal-title":"J Pharmacol Exp Ther."},{"issue":"1","key":"B3-20260109","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1053\/j.gastro.2014.05.027","article-title":"Drug-induced liver injury: morbidity, mortality, and Hy's law","volume":"147","author":"Regev","year":"2014","journal-title":"Gastroenterology."},{"issue":"3","key":"B4-20260109","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1053\/j.ajkd.2022.08.012","article-title":"Clinical pattern of tolvaptan-associated liver injury in trial participants with autosomal dominant polycystic kidney disease (ADPKD): an analysis of pivotal clinical trials","volume":"81","author":"Alpers","year":"2023","journal-title":"Am J Kidney Dis."},{"issue":"25","key":"B7-20260109","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","article-title":"Tolvaptan in patients with autosomal dominant polycystic kidney disease","volume":"367","author":"Torres","year":"2012","journal-title":"N Engl J Med."},{"issue":"11","key":"B9-20260109","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1007\/s40264-015-0327-3","article-title":"Clinical pattern of tolvaptan-associated liver injury in subjects with autosomal dominant polycystic kidney disease: analysis of clinical trials database","volume":"38","author":"Watkins","year":"2015","journal-title":"Drug Saf."},{"issue":"4","key":"B10-20260109","doi-asserted-by":"crossref","first-page":"100802","DOI":"10.1016\/j.xkme.2024.100802","article-title":"Tolvaptan and number needed to harm in autosomal dominant polycystic kidney disease","volume":"6","author":"Betts","year":"2024","journal-title":"Kidney Med."},{"issue":"3","key":"B11-20260109","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1093\/ndt\/gfx043","article-title":"Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial","volume":"33","author":"Torres","year":"2018","journal-title":"Nephrol Dial Transplant."},{"issue":"20","key":"B12-20260109","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1056\/NEJMoa1710030","article-title":"Tolvaptan in later-stage autosomal dominant polycystic kidney disease","volume":"377","author":"Torres","year":"2017","journal-title":"N Engl J Med."},{"issue":"3","key":"B13-20260109","doi-asserted-by":"crossref","first-page":"sfaf062","DOI":"10.1093\/ckj\/sfaf062","article-title":"Five years of post-marketing liver safety data from the tolvaptan risk evaluation and mitigation strategy","volume":"18","author":"Lohrmann","year":"2025","journal-title":"Clin Kidney J."},{"issue":"8","key":"B14-20260109","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1093\/ckj\/sfac076","article-title":"Evaluating the impact of a risk evaluation and mitigation strategy with tolvaptan to monitor liver safety in patients with autosomal dominant polycystic kidney disease","volume":"15","author":"Estilo","year":"2022","journal-title":"Clin Kidney J."},{"issue":"11","key":"B15-20260109","doi-asserted-by":"crossref","first-page":"sfae324","DOI":"10.1093\/ckj\/sfae324","article-title":"Liver safety of tolvaptan in patients with autosomal dominant polycystic kidney disease: interim data from a post-authorization safety study","volume":"17","author":"Jaeger","year":"2024","journal-title":"Clin Kidney J."},{"issue":"1","key":"B16-20260109","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1186\/s12882-021-02607-4","article-title":"Treatment persistence to tolvaptan in patients with autosomal dominant polycystic kidney disease: a secondary use of data analysis of patients in the IMADJIN\u00ae dataset","volume":"22","author":"Thomas","year":"2021","journal-title":"BMC Nephrol."},{"issue":"11","key":"B17-20260109","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1007\/s10157-021-02100-0","article-title":"Safety and efficacy of tolvaptan in real-world patients with autosomal dominant polycystic kidney disease- interim results of SLOW-PKD surveillance","volume":"25","author":"Mochizuki","year":"2021","journal-title":"Clin Exp Nephrol."},{"issue":"6","key":"B18-20260109","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s10157-025-02634-7","article-title":"Safety and efficacy of tolvaptan in real-world Japanese patients with autosomal dominant polycystic kidney disease: final results of SLOW-PKD surveillance","volume":"29","author":"Mochizuki","year":"2025","journal-title":"Clin Exp Nephrol."},{"key":"B19-20260109","article-title":"Evaluating the Safety and effectivenesS in adult KorEaN patients treated with Tolvaptan for management of autosomal domInAnt poLycystic kidney disease (ESSENTIAL): final report [published online ahead of print September 11, 2024]","author":"Park","journal-title":"Kidney Res Clin Pract."},{"issue":"5","key":"B21-20260109","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1093\/ndt\/gfab312","article-title":"An update on the use of tolvaptan for autosomal dominant polycystic kidney disease: consensus statement on behalf of the ERA working group on inherited kidney disorders, the European rare kidney disease reference network and polycystic kidney disease international","volume":"37","author":"M\u00fcller","year":"2022","journal-title":"Nephrol Dial Transplant."},{"issue":"2","key":"B22-20260109","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.kint.2024.07.010","article-title":"KDIGO 2025 clinical practice guideline for the evaluation, management, and treatment of autosomal dominant polycystic kidney disease (ADPKD): executive summary","volume":"107","author":"Torres","year":"2025","journal-title":"Kidney Int."},{"issue":"10","key":"B23-20260109","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1681\/ASN.2018060590","article-title":"A practical guide for treatment of rapidly progressive ADPKD with tolvaptan","volume":"29","author":"Chebib","year":"2018","journal-title":"J Am Soc Nephrol."},{"issue":"11","key":"B24-20260109","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1016\/j.ekir.2019.09.002","article-title":"Role of liver transplantation in tolvaptan-associated acute liver failure","volume":"4","author":"Endo","year":"2019","journal-title":"Kidney Int Rep."},{"issue":"1","key":"B25-20260109","doi-asserted-by":"crossref","first-page":"48","DOI":"10.2215\/CJN.10250620","article-title":"Multicenter study of long-term safety of tolvaptan in later-stage autosomal dominant polycystic kidney disease","volume":"16","author":"Torres","year":"2020","journal-title":"Clin J Am Soc Nephrol."}],"container-title":["Kidney360"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.34067\/KID.0000000934","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T19:59:51Z","timestamp":1786478391000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.34067\/KID.0000000934"}},"subtitle":["Is Hepatotoxicity Still a Concern?"],"short-title":[],"issued":{"date-parts":[[2025,7,21]]},"references-count":20,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.34067\/kid.0000000934","relation":{},"ISSN":["2641-7650"],"issn-type":[{"value":"2641-7650","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,21]]}}}